RIA · CRD 329873SEC-RegisteredPrivate Fund Adviser

Updated:

Benchstone Capital Management

BENCHSTONE CAPITAL MANAGEMENT LP is an SEC-registered investment adviser in NEW YORK, NY, registered since 2024. The firm manages approximately $1.1 billion in...

Benchstone Capital Management

BENCHSTONE CAPITAL MANAGEMENT LP is an SEC-registered investment adviser in NEW YORK, NY, registered since 2024. The firm manages approximately $1.1 billion in assets. It has 11 employees and 7 investment advisers.

General information

Firm type

RIA

Year founded

2010

Location

Region

North America

Country

United States

City

New York

Corporate office

Fort Worth, TX, United States

Principals

Robert Bass

Principal

Sector focus

Energy Transition & RenewablesReal EstatePrivate CreditHedge FundsEnterprise SoftwareInfrastructure

Frequently asked questions

How does Benchstone Capital Management source proprietary deal flow?

Benchstone relies on a network built over four decades by Robert Bass, encompassing private equity sponsors, direct company relationships, and a small circle of co-investing peers. The firm does not operate a formal outbound sourcing team. Its willingness to write large, patient checks and accept custom structures attracts opportunities from sponsors who value certainty of close over auction dynamics.

Does Benchstone participate in fund commitments or only direct deals?

Benchstone engages in both. Its direct activity focuses on private equity co-investments, real estate, and energy infrastructure. Simultaneously, it has made substantial limited-partner commitments to venture funds from managers including Spark Capital and Founders Fund, using the fund portfolio to access early-stage technology exposure without building an in-house venture team.

Which sectors does Benchstone Capital Management explicitly avoid?

Benchstone has consistently avoided sectors characterized by short-cycle consumer demand and high-fashion risk, such as apparel and branded consumer goods. It also exhibits no public record of investing in biotechnology or pharmaceutical development, areas that require specialized scientific diligence and carry binary regulatory risk unsuited to the firm's generalist team structure.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on registered investment advisers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More New York RIA profiles